Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently bonded to estrogen receptor-α (ERα)-targeting moiety through a linker reported to be useful for the treatment of breast cancer and infections.
Mablink Bioscience SAS., Université Claude Bernard Lyon 1 and Centre National de la Recherche Scientifique have patented antibody-drug conjugates consisting of antibodies covalently linked to therapeutic drugs through an enzyme-triggered self-immolative linker reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Lattice Medical SAS reported the first successful breast reconstruction using Mattisse technology, a totally resorbable, 3D-printed implant which naturally regenerates fatty tissue. The procedure was performed at the Institute of Clinical Oncology in Tbilisi, Georgia. It was the work of cancer specialist Gia Nemsadze and his team. This was an immediate breast reconstruction for a 62-year-old patient with breast cancer. The surgical procedure lasted one and a half hours, allowing the mastectomy to be completed, immediately followed by the breast reconstruction.
In an expansion that will surely have other companies wondering why they didn’t move on the opportunity first, Icad Inc. partnered with Solis Mammography to identify cardiovascular risk based on incidental information commonly found in mammograms—and generally ignored.
Shenzhen Forward Pharmaceutical Co. Ltd. has divulged estrogen receptor α (ERα) antagonists and/or degradation inducers reported to be useful for the treatment of cancer.
A new ultrasound-based technique has been developed to overcome the shortcomings of conventional X-ray mammography in screening younger women whose breast density is high.
Vergent Bioscience Inc. raised $21.5 million in a series B financing round to advance development of VGT-309, its targeted fluorescent imaging agent that illuminates tumors during open, minimally invasive and robotic-assisted surgeries. The company plans to use the funds to support a phase II trial at the University of Pennsylvania that focuses on lung cancer and a multicenter study that will examine the agent’s use in other indications.
Delphinus Medical Technologies Inc. raised $30.4 million in a series D fundraising round to support worldwide commercialization of its Softvue 3D whole breast ultrasound tomography system. Both new and existing investors kicked in funds including Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures and Waycross Ventures.
